
    
      This is a phase II study with two parallel cohorts of newly diagnosed multiple myeloma (NDMM)
      patients in at least partial response (PR) after induction with proteasome inhibitors (PIs)
      plus IMIDs and single or double ASCT Subjects will receive two dose levels of Iberdomide,
      they will be evaluated for efficacy and safety. In case, in one cohort will be registered
      unacceptable toxicity, a third cohort will be opened. Subjects will receive treatment until
      progression, intolerance or unacceptable toxicity. Subsequently subjects will be followed for
      24 months. The maximum number of subjects is 130 for cohort 1 and 2, 160 in case a third
      cohort will be opened.
    
  